Entasis Therapeutics Holdings Inc. (ETTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
ETTX Stock Price Chart Interactive Chart >
ETTX Price/Volume Stats
| Current price | $2.19 | 52-week high | $3.88 |
| Prev. close | $2.19 | 52-week low | $1.40 |
| Day low | $2.19 | Volume | 31,700 |
| Day high | $2.20 | Avg. volume | 246,730 |
| 50-day MA | $2.02 | Dividend yield | N/A |
| 200-day MA | $2.26 | Market Cap | 104.80M |
Entasis Therapeutics Holdings Inc. (ETTX) Company Bio
Entasis Therapeutics Inc. discovers and develops antibacterials to fight diseases caused by multidrug-resistant bacteria. It offers ETX2514, a broad-spectrum and potent inhibitor of class A, C, and D beta-lactamases that has activity against Acinetobacter baumannii, a gram-negative bacterium that causes severe infections, which are associated with high mortality; ETX0914, a novel oral antibiotic for the treatment of uncomplicated gonorrhea; and a drug discovery platform that focuses on developing novel antibacterials targeting serious gram-negative infections, such as pneumonia, infections of the blood, urinary tract infections, and infections following surgery. Entasis Therapeutics Inc. has strategic development collaboration with Zai Lab Limited. The company was founded in 2015 and is based in Waltham, Massachusetts. Entasis Therapeutics Inc. operates as a subsidiary of AstraZeneca PLC.
Latest ETTX News From Around the Web
Below are the latest news stories about Entasis Therapeutics Holdings Inc that investors may wish to consider to help them evaluate ETTX as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayGood morning, investor! |
Entasis gains on buyout proposal from InnovivaEntasis Therapeutics (ETTX) is trading ~15% higher in the pre-market after announcing that its existing investor, Innoviva submitted a non-binding proposal to buy the shares it |
Entasis Therapeutics Receives Acquisition Proposal from Existing Majority Stockholder Innoviva Inc.WALTHAM, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that its Board of Directors received a preliminary, non-binding proposal from its majority stockholder Innoviva, Inc. (“Innoviva”) to acquire all of the outstanding equity securities of Entasis that are not currently owned by Innoviva for a per share consideration o |
Entasis Therapeutics to Participate in H.C. Wainwright BioConnect 2022WALTHAM, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that the Company will be participating in the H.C. Wainwright BioConnect 2022 investor conference, to be held virtually from January 10-13, 2022. Details for the event and management’s participation are as follows: H.C. Wainwright BioConnect 2022Dates: January |
-$0.26 EPS Expected for Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) This QuarterEquities research analysts expect that Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) will post earnings per share of ($0.26) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Entasis Therapeutics earnings, with the highest EPS estimate coming in at ($0.25) and the lowest estimate coming in at ($0.26). Entasis Therapeutics posted earnings [] |
ETTX Price Returns
| 1-mo | N/A |
| 3-mo | 17.11% |
| 6-mo | 0.00% |
| 1-year | -20.07% |
| 3-year | -66.05% |
| 5-year | N/A |
| YTD | 0.00% |
| 2021 | -11.34% |
| 2020 | -50.30% |
| 2019 | 22.11% |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...